← Back to Search

Selective Serotonin Reuptake Inhibitor

Escitalopram for Sperm DNA Fragmentation

Phase 2
Recruiting
Led By Jonathan Gal, MD
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Current psychiatric disorder including: bipolar, mania, depression, generalized anxiety, social phobia, panic attacks, obsessive compulsive disorder, and schizophrenia
Family history of bipolar disorder, or suicide (including 2nd degree relatives)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 (baseline), 6, 10 weeks
Awards & highlights

Summary

This trial is testing the effects of escitalopram, a common antidepressant, on healthy men with normal fertility and no history of mental health issues. Researchers want to see if this medication affects sperm quality and overall fertility. The results will help doctors advise men who are concerned about fertility and are taking or considering taking escitalopram.

Who is the study for?
Men with normal or slightly low sperm counts who are not currently trying to conceive and have no psychiatric disorders, liver disease, family history of bipolar disorder or suicide. Participants must be able to engage in weekly sexual activity and provide semen samples throughout the 10-week study.
What is being tested?
The trial is testing if Escitalopram affects sperm DNA quality over a period of 6 weeks compared to a placebo. It's a double-blind study, meaning neither participants nor researchers know who gets the real drug. Measurements include hormone levels, semen analysis, and sexual function.
What are the potential side effects?
Potential side effects from Escitalopram may include nausea, headache, trouble sleeping, dry mouth, increased sweating, feeling nervous or restless; sexual side effects like reduced libido or difficulty achieving orgasm can also occur.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a diagnosed psychiatric condition like depression or anxiety.
Select...
My family has a history of bipolar disorder or suicide.
Select...
I am currently taking medication for mental health or seizures.
Select...
I use sleeping pills.
Select...
I use medication to improve sexual function.
Select...
I have had chemotherapy or radiation to the pelvis.
Select...
I have not used hormonal medications in the last 3 months.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 (baseline), 6, 10 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 (baseline), 6, 10 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of patients converted from normal to abnormal sperm DNA fragmentation from baseline to 6 weeks
Secondary study objectives
Absolute change in sperm DNA fragmentation
Changes in concentration
Changes in progressive motility
+2 more
Other study objectives
Change in International Index of Erectile Function Survey
Change in serum follicle-stimulating hormone (FSH) (mIU/mL)
Change in serum luteinizing hormone (LH) (mIU/mL)
+2 more

Side effects data

From 2019 Phase 4 trial • 115 Patients • NCT01902004
23%
Sleepiness/Sedation
10%
Headache
8%
Tension/Inner Unrest
8%
Reduced Salivation
8%
Concentration Difficulties
8%
Diminished Sexual Drive
6%
Asthenia/Lassitude/Increased Fatigability
6%
Constipation
6%
Polyuria/Polydipsia
6%
Orthostatic Dizziness
4%
Nausea/Vomiting
4%
Erectile Dysfunction
4%
Failing Memory
2%
Diarrhea
2%
Increased Duration of Sleep
2%
Reduced Duration of Sleep
2%
Increased Dream Activity
2%
Accomodation Disturbance
2%
Increased Tendancy to Sweating
2%
Weight Gain
2%
Ejaculatory Dysfunction
2%
Micturtion Disturbances
100%
80%
60%
40%
20%
0%
Study treatment Arm
Escitalopram and Placebo
Escitalopram and Memantine

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: EscitalopramExperimental Treatment1 Intervention
10mg by mouth daily for 6 weeks
Group II: PlaceboPlacebo Group1 Intervention
Matched placebo control by mouth for 6 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Escitalopram
2005
Completed Phase 4
~2330

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for male infertility include medications like Selective Serotonin Reuptake Inhibitors (SSRIs), which increase serotonin levels in the brain. While SSRIs like Escitalopram are primarily used to treat depression, they can negatively impact semen quality by increasing sperm DNA fragmentation and reducing sperm concentration and morphology. Other treatments, such as Coenzyme Q10 and L-carnitine, work by improving mitochondrial function and energy production in sperm cells, enhancing motility and overall sperm health. Follicle-stimulating hormone (FSH) and tamoxifen can stimulate sperm production and improve hormonal balance. Understanding these mechanisms is crucial for male infertility patients as it helps them and their doctors make informed decisions about treatment options that balance mental health needs with reproductive goals.
The antidepressant Sertraline inhibits CatSper Ca2+ channels in human sperm.The effect of SSRIs on Semen quality: A systematic review and meta-analysis.Effect of Venlafaxine, Pramipexole, and Valsartan on Spermatogenesis in Male Rats.

Find a Location

Who is running the clinical trial?

Weill Medical College of Cornell UniversityLead Sponsor
1,077 Previous Clinical Trials
1,320,597 Total Patients Enrolled
Jonathan Gal, MDPrincipal InvestigatorWeill Medical College of Cornell University
2 Previous Clinical Trials
140 Total Patients Enrolled
Peter Schlegel, MDPrincipal InvestigatorWeill Medical College of Cornell University
1 Previous Clinical Trials
69 Total Patients Enrolled

Media Library

Escitalopram (Selective Serotonin Reuptake Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03527043 — Phase 2
Male Infertility Research Study Groups: Escitalopram, Placebo
Male Infertility Clinical Trial 2023: Escitalopram Highlights & Side Effects. Trial Name: NCT03527043 — Phase 2
Escitalopram (Selective Serotonin Reuptake Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03527043 — Phase 2
~26 spots leftby Dec 2028